Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease
about
Inhibition of retinoic acid-inducible gene I-mediated induction of beta interferon by the NS1 protein of influenza A virusGenetically engineered Newcastle disease virus for malignant melanoma therapyRecombinant Newcastle disease virus as a vaccine vector for cancer therapyInhibition of the type I interferon response in human dendritic cells by dengue virus infection requires a catalytically active NS2B3 complexEngineered newcastle disease virus as an improved oncolytic agent against hepatocellular carcinomaEnhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responsesLive attenuated influenza viruses containing NS1 truncations as vaccine candidates against H5N1 highly pathogenic avian influenzaNewcastle Disease Virus as a Vaccine Vector for Development of Human and Veterinary VaccinesCurrent Status of Veterinary VaccinesNewcastle disease virus-based live attenuated vaccine completely protects chickens and mice from lethal challenge of homologous and heterologous H5N1 avian influenza viruses.Vesicular stomatitis virus vectors expressing avian influenza H5 HA induce cross-neutralizing antibodies and long-term protection.Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.Influenza A virus strains differ in sensitivity to the antiviral action of Mx-GTPaseProtection of chickens against avian influenza with non-replicating adenovirus-vectored vaccineAvian influenza vaccination in chickens and pigs with replication-competent adenovirus-free human recombinant adenovirus 5Ecology of avian influenza viruses in a changing worldNew strategies for the development of H5N1 subtype influenza vaccines: progress and challenges.Human pulmonary microvascular endothelial cells support productive replication of highly pathogenic avian influenza viruses: possible involvement in the pathogenesis of human H5N1 virus infection.Protective efficacy of Newcastle disease virus expressing soluble trimeric hemagglutinin against highly pathogenic H5N1 influenza in chickens and mice.Experimental vaccines against potentially pandemic and highly pathogenic avian influenza virusesImmunization of chickens with Newcastle disease virus expressing H5 hemagglutinin protects against highly pathogenic H5N1 avian influenza viruses.Contributions of the avian influenza virus HA, NA, and M2 surface proteins to the induction of neutralizing antibodies and protective immunityAssembly and biological and immunological properties of Newcastle disease virus-like particles.Virus-vectored influenza virus vaccines.Generation of replication-competent recombinant influenza A viruses carrying a reporter gene harbored in the neuraminidase segmentInhibition of Pseudomonas aeruginosa with a recombinant RNA-based viral vector expressing human β-defensin 4.Induction of type I interferon secretion through recombinant Newcastle disease virus expressing measles virus hemagglutinin stimulates antibody secretion in the presence of maternal antibodiesImproved hatchability and efficient protection after in ovo vaccination with live-attenuated H7N2 and H9N2 avian influenza viruses.Newcastle disease virus expressing a dendritic cell-targeted HIV gag protein induces a potent gag-specific immune response in mice.Chimeric newcastle disease virus protects chickens against avian influenza in the presence of maternally derived NDV immunitySuccess factors for avian influenza vaccine use in poultry and potential impact at the wild bird-agricultural interface.Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancerNonsegmented negative-strand viruses as vaccine vectors.Newcastle disease virus-vectored rabies vaccine is safe, highly immunogenic, and provides long-lasting protection in dogs and catsGeneration of influenza virus from avian cells infected by Salmonella carrying the viral genomeNewcastle Disease Virus-Vectored H7 and H5 Live Vaccines Protect Chickens from Challenge with H7N9 or H5N1 Avian Influenza Viruses.Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma.Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancerAvian paramyxovirus serotypes 2-9 (APMV-2-9) vary in the ability to induce protective immunity in chickens against challenge with virulent Newcastle disease virus (APMV-1).Newcastle disease virus, a host range-restricted virus, as a vaccine vector for intranasal immunization against emerging pathogens.
P2860
Q24311228-54EE68DB-D69A-48C2-ADD6-8407DBCC42B8Q24597831-A8E1DF15-4E02-47DB-A6F1-5B33A68EEC18Q24602728-1E694CD4-48CF-4A7C-AD43-B435310E676DQ24611465-CD4378B5-6C41-48AE-94E4-B91FA7690145Q24628144-7DD268E4-D804-4CAB-B7F8-E5D26DAD7A3DQ24631361-9C1430EE-5C5B-4952-9E36-23FDAA9F6824Q24652088-416920A0-C0D9-4647-A5DD-CBB7CFDDB0EFQ26744220-974D39C2-59F9-4ECD-8884-99E18C378B67Q27480923-6BCC88BD-E02F-46C3-A893-F0CF483A2092Q30357521-9EFBEFCC-3DEC-4A54-A765-5258C0005E06Q30361939-C41D5EC7-E1FD-4193-90AD-C3046A7D5578Q30363581-4CF119B7-2133-4701-AAA2-0639261BBD4FQ30367187-F2EDF9F0-CB9F-4B83-A29D-069C532713CEQ30368615-9E828609-64DD-48F0-8546-A148A5C0DD5BQ30389956-2F7515F5-1092-4668-A7DE-A83740768250Q30390198-003F39A4-8465-4AD2-BDFE-814C55403791Q30407424-DE1D07F7-F80E-459C-BBBF-811A4D724AE0Q30409253-21AEA06F-4665-4DB6-AFF0-7B7B92D37402Q30421007-F1A476BD-1AB1-44B5-89B3-53D769E39FC7Q30427591-4C9139AC-CB54-4A67-A102-F5E5968B5B59Q33490614-8E1B4A46-6AA6-4F8A-AD79-C47955DA13FBQ33648987-04D80516-06DF-4ED2-8F1A-A2E9B4090768Q33826688-0D4AD6ED-82F5-4BB8-8C3E-F5B3F4B7D5B0Q34102268-AC1D6037-3497-44C4-9850-C7B607C10880Q34296134-B09BA460-649A-4EE5-89C0-BA78F03FB4E2Q34304129-2F65FFFD-4166-4227-AD27-DE16933F8BB1Q34457996-6F00F805-B15B-48CB-AEAD-FBF6D0FFD3FEQ34547300-44673AF6-530A-4910-8132-D3D2E61DF81BQ34741882-1A40E981-EB09-4B15-81B7-70884E7C8039Q34983940-AFAC5FBB-1B4F-47C2-AA34-F07AE4566EEBQ34985416-0FC160F5-A399-40B0-84B7-0CB87BE771FCQ35050645-4888EAA8-A0D6-4CAE-8295-CE1882C7F37AQ35139219-D9EF638D-6030-4932-922D-271DA6242559Q35140435-33086B46-0C28-468C-B15F-2E3B41789E2EQ35572130-7A5AEDDC-B2C9-4556-9AD8-0D2AEB6FB09FQ35618503-C9AC032A-8806-49D2-AD67-A0A7A118600AQ35699080-3A46558A-DD96-4B84-8CEE-31C69A3801CEQ35720107-0DCA798B-CA8C-4151-B262-62F626392A67Q35790333-287ADBA2-E35B-4F0C-8E8B-31E088245D29Q35834369-FF3458A5-A902-4AFF-9043-5D0AA35953B2
P2860
Engineered viral vaccine constructs with dual specificity: avian influenza and Newcastle disease
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@ast
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@en
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@nl
type
label
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@ast
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@en
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@nl
prefLabel
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@ast
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@en
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@nl
P2093
P2860
P356
P1476
Engineered viral vaccine const ...... nfluenza and Newcastle disease
@en
P2093
David Swayne
John Steel
Man-Seong Park
P2860
P304
P356
10.1073/PNAS.0602566103
P407
P577
2006-05-22T00:00:00Z